SAN RAMON, Calif., February 17, 2021—CooperVision Specialty EyeCare has named Marie-Christine Blanchard as Global Lead, Irregular Cornea. She is now responsible for overseeing category growth across the company, including guiding cross-functional teams in support of the increasing number of eye care professionals adopting technologies such as scleral contact lenses.
Prior to the promotion, Ms. Blanchard was the scleral lens lead for the Americas region and was responsible for commercial and manufacturing operations for CooperVision Specialty EyeCare in Canada. Her work with the company began during her formative years, having grown up in the contact lens business with the guidance of her grandfather and father, the renowned Jean-Louis Blanchard and Jean Blanchard, respectively. She is a licensed optician, holds a baccalaureate in business marketing, and earned her MBA in International Business through a joint degree program from the University of Sherbrooke (Canada) and ESCEM (France).
“Marie’s broad and deep category experience will prove invaluable as we expand our global irregular cornea and scleral lens efforts. CooperVision’s innovative scleral designs, technical support services, extensive myopia management investments, and commitment to specialty lenses are well known. With Marie’s leadership, we will make even more strides in partnership with eye care professionals to improve vision and enhance lives,” said Dr. Juan Carlos Aragón, President, CooperVision Specialty EyeCare.
CooperVision Specialty EyeCare develops, manufacturers, and provides access to a portfolio of industry leading soft custom and rigid gas permeable lens designs, including orthokeratology and scleral lenses to address segments such as myopia management, irregular cornea management and presbyopia management. Its steady voice, ongoing research and innovative products and services play a leading role in expanding care worldwide. The group’s brands include Blanchard, GP Specialists, Paragon, Procornea and Soflex.
# # #
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA, McDougall Communications
email@example.com or +1-585-434-2150